Stamford, CT -- (SBWIRE) -- 11/02/2013 -- OTC Stock Picks is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: Barrick Gold Corporation (USA) (NYSE:ABX), Amarin Corporation plc (ADR) (NASDAQ:AMRN), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)
Barrick Gold Corporation (USA) (NYSE:ABX) ended higher -7.12% and complete the day at $18.01. The total number of shares changed hands during the day was 74.46 million. After opening at $18.16, the stock hit as high as $18.46. However, it traded between $13.43 and $38.00 over the last twelve months.
Stocks graphical chart shows a bearish trend during its last one month’s trading session. It remained positive +7.14% during the previous three months trade. Barrick Gold Corporation engages in the production and sale of gold and copper. It is also involved in exploration and mine development activities. The company holds interests in the producing gold mines, which are concentrated in North America, South America, and Australia Pacific; producing copper mines located in Chile and Zambia.
Has ABX Found The Bottom and Ready To Move Up? Find Out Here
Amarin Corporation plc (ADR) (NASDAQ:AMRN) moved -0.55 percent lower at $1.64 and traded between $1.59 and $1.69 after opening the day at $1.65. Its performance over the last five days remained -24.75%, which stands at -74.79% for a month. Going back further than one month, 1-year performance after recent close was -79.72%.
The company has a total of 172.14 million outstanding shares and its total market capitalization is $282.49 million. Its beta value stands at 1.11 times and earnings per share was -$0.92. Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids.
Why Should Investors Buy AMRN After the Recent Fall? Just Go Here and Find Out
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares rose, +17.27 percent to close at $2.58. The stock is up around -86.55% this year and -88.17% for the last 12 months. Around 21.94 million shares changed hands yesterday, higher from an-average trading volume of 18.83 million shares. ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicin.
Why Should Investors Buy ARIA After The Recent Gain? Just Go Here and Find Out
About OTC Stock Picks
The team is among the US market leaders in connecting stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse’ of the stock market. The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter. The company offers investors Free Level II service and Free Real Time Stock Charts on its company website.
OTC Stock Picks is not a registered securities adviser. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.
Read full disclaimer at: http://otcstockpicks.net/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)